Neurocrine Biosciences launches CRENESSITY for classic CAH at WAC ~$38,333/month

NEUROCRINE BIOSCIENCES INC

CRENESSITY commercially available in U.S. for classic CAH (ages 4+); dispensed exclusively via PANTHERx Rare specialty pharmacy.
Wholesale acquisition cost ~$38,333/30-day supply for adults; ~$19,167 for pediatric patients <20 kg.
Company expects 90% of patients will have monthly copay of $12 or less through Neurocrine Access Support.
CAH-trained pharmacists available 24/7 via PANTHERx Rare; free support program for patients and providers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.